Chaoyun Li
Shanghai, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Lixisenatide for Type 2 Diabetes Mellitus Patients Inadequately Controlled on Oral Antidiabetic Drugs: A Mixed-Treatment Comparison Meta-analysis and Cost-Utility Analysis.
Journal: Diabetes therapy : research, treatment and education of diabetes and related disorders
Published: May 09, 2020
Comparative cost-effectiveness of amisulpride and olanzapine in the treatment of schizophrenia in China.
Journal: Expert review of pharmacoeconomics & outcomes research
Published: April 16, 2020
Lixisenatide versus insulin glulisine on top of insulin glargine in patients with type 2 diabetes mellitus: a cost-per-responder analysis in China.
Journal: Current medical research and opinion
Published: August 31, 2019
Epidemiological characteristics, medical costs and healthcare resource utilization of diabetes-related complications among Chinese patients with type 2 diabetes mellitus.
Journal: Expert review of pharmacoeconomics & outcomes research
Published: August 29, 2019
Meta-Analysis and Cost-Effectiveness Analysis of Insulin Glargine 100 U/mL Versus Insulin Degludec for the Treatment of Type 2 Diabetes in China.
Journal: Diabetes therapy : research, treatment and education of diabetes and related disorders
Published: April 01, 2019
Comparison of lixisenatide in combination with basal insulin vs other insulin regimens for the treatment of patients with type 2 diabetes inadequately controlled by basal insulin: Systematic review, network meta-analysis and cost-effectiveness analysis.
Journal: Diabetes, obesity & metabolism
Published: March 13, 2019
Comparative efficacy and safety between amisulpride and olanzapine in schizophrenia treatment and a cost analysis in China: a systematic review, meta-analysis, and cost-minimization analysis.
Journal: BMC psychiatry
Published: January 15, 2018
Showing 1-8 of 8
Last Updated: 09/26/2026